Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment

Lirong Zhang; Xiaodong Ma; Wenhui Zhou; Qiwei Wu; Jiaqi Yan; Xiaoyu Xu; Bhawana  Ghimire; Jessica M. Rosenholm; Jing Feng; Dongqing Wang; Hongbo Zhang

doi:10.1016/j.mtadv.2021.100199

Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment

Lirong Zhang, Xiaodong Ma, Wenhui Zhou, Qiwei Wu, Jiaqi Yan, Xiaoyu Xu, Bhawana Ghimire, Jessica M. Rosenholm, Jing Feng, Dongqing Wang, Hongbo Zhang^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

8 Citations (Scopus)

32 Downloads (Pure)

Abstract

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles (Au@MSN-NH2 NPs). Subsequently, doxorubicin (DOX) was loaded into the Au@PTXSS-MSN NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged Au@PTXSS-MSN/DOX@CM NPs. The Au@PTXSS-MSN/DOX@CM NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of Au@PTXSS-MSN/DOX@CM NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.

Original language	English
Article number	100199
Journal	Materials Today Advances
Volume	13
DOIs	https://doi.org/10.1016/j.mtadv.2021.100199
Publication status	Published - Mar 2022
MoE publication type	A1 Journal article-refereed

Access to Document

10.1016/j.mtadv.2021.100199

Zhang et al., 2021 Mater Today AdvFinal published version, 3.19 MBLicence: CC BY

FCFH: Finland-China Network in Food and Health Sciences
Rosenholm, J., Xu, C. & Zhang, H.
Ministry of Education and Culture
01/01/21 → 31/12/24
Project: Ministry / Government Agency
InFLAMES: Innovation Ecosystem based on the Immune System
Takeda, A., Marjamäki, A., Roivainen, A., Hakanen, A., Hänninen, A., Sahlgren, C., Julkunen, I., Ivaska, J., Eriksson, J., Jorma, T., Rinne, J., Knuuti, J., Westermarck, J., Jyrki, H., Gidwani, K., Elima, K., Aires, L., Elo, L. L., Hollmen, M., Johnson, M., Salmi, M., Oresic, M., Poutanen, M., Kortelainen, M., Pentikäinen, O., Raitakari, O., Jaakkola, P., Salminen, P., Taimen, P., Vallittu, P., Rantakari, P., Mattila, P., Nuutila, P., He, Q., Lahesmaa, R., De Figueiredo, R., Jalkanen, S., Lönnberg, T., Soukka, T., Salminen, T. A., Veromaa, T., Lamminmäki, U., Launis, V., Peltola, V., Xiang-Guo, L., Coffey, E., Meinander, A., Toivola, D. & Zhang, H.
01/07/20 → 30/04/23
Project: Academy of Finland/Other Research Councils
Targeted delivery of CRISPR/Cas9 for advanced liver cancer therapy through c-Myc knockout
Zhang, H.
01/09/19 → 31/08/24
Project: Academy of Finland/Other Research Councils

Cite this

@article{02b594ae10ed4103a5010478766d8050,

title = "Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment",

abstract = "Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles (Au@MSN-NH2 NPs). Subsequently, doxorubicin (DOX) was loaded into the Au@PTXSS-MSN NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged Au@PTXSS-MSN/DOX@CM NPs. The Au@PTXSS-MSN/DOX@CM NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of Au@PTXSS-MSN/DOX@CM NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.",

author = "Lirong Zhang and Xiaodong Ma and Wenhui Zhou and Qiwei Wu and Jiaqi Yan and Xiaoyu Xu and Bhawana Ghimire and Rosenholm, {Jessica M.} and Jing Feng and Dongqing Wang and Hongbo Zhang",

year = "2022",

month = mar,

doi = "10.1016/j.mtadv.2021.100199",

language = "English",

volume = "13",

journal = "Materials Today Advances",

issn = "2590-0498",

publisher = "Elsevier Doyma",

}

TY - JOUR

T1 - Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment

AU - Zhang, Lirong

AU - Ma, Xiaodong

AU - Zhou, Wenhui

AU - Wu, Qiwei

AU - Yan, Jiaqi

AU - Xu, Xiaoyu

AU - Ghimire, Bhawana

AU - Rosenholm, Jessica M.

AU - Feng, Jing

AU - Wang, Dongqing

AU - Zhang, Hongbo

PY - 2022/3

Y1 - 2022/3

N2 - Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles (Au@MSN-NH2 NPs). Subsequently, doxorubicin (DOX) was loaded into the Au@PTXSS-MSN NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged Au@PTXSS-MSN/DOX@CM NPs. The Au@PTXSS-MSN/DOX@CM NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of Au@PTXSS-MSN/DOX@CM NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.

AB - Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles (Au@MSN-NH2 NPs). Subsequently, doxorubicin (DOX) was loaded into the Au@PTXSS-MSN NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged Au@PTXSS-MSN/DOX@CM NPs. The Au@PTXSS-MSN/DOX@CM NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of Au@PTXSS-MSN/DOX@CM NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.

U2 - 10.1016/j.mtadv.2021.100199

DO - 10.1016/j.mtadv.2021.100199

M3 - Article

SN - 2590-0498

VL - 13

JO - Materials Today Advances

JF - Materials Today Advances

M1 - 100199

ER -

Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment

Abstract

Access to Document

Fingerprint

Projects

FCFH: Finland-China Network in Food and Health Sciences

InFLAMES: Innovation Ecosystem based on the Immune System

Targeted delivery of CRISPR/Cas9 for advanced liver cancer therapy through c-Myc knockout

Cite this